|
(L1) 608.69639-Provision Of Services, Rental Of Coagulation Equipment, Additional Characteristics: Other Information In Accordance With The Terms Of Reference And/Or Technical Description Of The Process, Units. Measurement: Unit, (L2) 6607.37717-Reactive For Determination Of Prothrombin Time (Tap), Presentation: One-Stage Quick Method, Freeze-Dried Thromboplastin Obtained From Rabbit Brain, Calcium Chloride And Sodium Chloride, O Reactive Must Be Free From Contamination, Shelf Life: Must Be At Least 2/3 Of The Total Shelf Life, On The Date Of Receipt, Packaging: Labelled, Sealed, Resistant And Undamaged Box, Accompanied By A Leaflet With At Least 10 Vials Of Lyophilized Reactive Duly Labeled Individually, Additional Characteristics: Bring Identification Data, Storage Conditions, Batch Number, Expiration Date And Registration Number With The Ministry Of Health On The Label, (L3) 6605.25123-Reactive For The Determination Of Partial Thromboplastin Time Activated (Ttpa), Containing Cephaline And Kaolin Or Micronized Silica As Activators, Accompanied By Calcium Chloride At 0.025 Mol/L Ready To Use (Included). The Reagent Must Have Excellent Sensitivity To The Factors Of The Intrinsic Pathway, Mainly To Factors Viii And Ix And Improved Or Increased Sensitivity To Lupus Anticoagulant, Validity: Minimum Of 10 Months After Delivery Of The Product, Packaging: Must Contain Identification Data, Number Of Batch, Registration With The Ministry Of Health, Date Of Manufacture, (L4) 6605.80777-Reactive, Use: Quantitative Determination Of D-Dimer, Presentation: Containing Suspension Of Latex Microparticles, Covered With Two Types Of Mouse Monoclonal Antibodies, Anti-D -Human Dimer Stabilized With Bovine Albumin And Heterophilic Antibody Blocking Reagent, Validity: Minimum 12 Months After Product Delivery, (L5) 6605.80776-Reactive, Use: Quantitative Determination Of Fibrinogen, Presentation: Containing Titrated Calcium Thrombin (Approx. 100 Units Nih/Ml), Of Human Origin With A Specific Heparin Inhibitor That Allows The Quantification Of Fibrinogen In The Plasma Of Patients Treated With This Anticoagulant
|
